A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR)
暂无分享,去创建一个
K. Fisher | T. Maughan | D. Sebag‐Montefiore | J. Holmes | Richard J. P. Brown | M. Hawkins | Leonard W Seymour | S. Davis | J. Good | R. Adams | S. O’Cathail
[1] J. Machiels,et al. A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE) , 2019, Journal of Immunotherapy for Cancer.
[2] P. Tran,et al. Clinical Development of Novel Drug–Radiotherapy Combinations , 2018, Clinical Cancer Research.
[3] T. Hothorn,et al. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] Publisher's Note , 2018, Anaesthesia.
[5] T. Hothorn,et al. Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer , 2017, Journal of the National Cancer Institute.
[6] R. Salazar,et al. Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection , 2017, Journal of Immunotherapy for Cancer.
[7] L. Seymour,et al. Combining Oncolytic Adenovirus with Radiation—A Paradigm for the Future of Radiosensitization , 2017, Front. Oncol..
[8] M. Mulcahy,et al. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study. , 2017, The lancet. Gastroenterology & hepatology.
[9] D. Joseph,et al. Acute Adverse Events and Postoperative Complications in a Randomized Trial of Preoperative Short-course Radiotherapy Versus Long-course Chemoradiotherapy for T3 Adenocarcinoma of the Rectum: Trans-Tasman Radiation Oncology Group Trial (TROG 01.04) , 2017, Annals of surgery.
[10] D. Ferguson,et al. Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators , 2016, Molecular therapy oncolytics.
[11] Richard A. Adams,et al. Clinical development of new drug–radiotherapy combinations , 2016, Nature Reviews Clinical Oncology.
[12] T. Greenhalgh,et al. Combination of Novel Agents with Radiotherapy to Treat Rectal Cancer. , 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).
[13] C. Allegra,et al. Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials , 2015, Current Colorectal Cancer Reports.
[14] T. Hothorn,et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. , 2015, The Lancet. Oncology.
[15] T. DeWeese,et al. Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer. , 2014, International journal of radiation oncology, biology, physics.
[16] R. Weichselbaum,et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[17] R. Weichselbaum,et al. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] Kenneth J. Chang,et al. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. , 2012, Gastrointestinal endoscopy.
[19] R. Grossman,et al. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] G. Stewart,et al. Serotype-Specific Inactivation of the Cellular DNA Damage Response during Adenovirus Infection , 2010, Journal of Virology.
[21] T. DeWeese,et al. Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer , 2010, International journal of radiation biology.
[22] Steve Thorne,et al. Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer , 2008, PloS one.
[23] Michael Branson,et al. Critical aspects of the Bayesian approach to phase I cancer trials , 2008, Statistics in medicine.
[24] Stephen L. Brown,et al. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[25] Laurence Collette,et al. Chemotherapy with preoperative radiotherapy in rectal cancer. , 2006, The New England journal of medicine.
[26] P. Fisher,et al. Ionizing radiation enhances adenoviral vector expressing mda‐7/IL‐24‐mediated apoptosis in human ovarian cancer , 2006, Journal of cellular physiology.
[27] J. Bell,et al. Recent progress in the battle between oncolytic viruses and tumours , 2005, Nature Reviews Cancer.
[28] E. B. Butler,et al. Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients. , 2005, International journal of radiation oncology, biology, physics.
[29] P. Working,et al. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity , 2005, Cancer Gene Therapy.
[30] Rainer Fietkau,et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.
[31] R. Weichselbaum,et al. A Phase I Trial of TNFerade Biologic in Patients with Soft Tissue Sarcoma in the Extremities , 2004, Clinical Cancer Research.
[32] J. Zalcberg,et al. A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer , 2004, British Journal of Cancer.
[33] K. Ulbrich,et al. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus , 2004, Gene Therapy.
[34] R. Weichselbaum,et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] P. Opolon,et al. Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts , 2003, British Journal of Cancer.
[36] J. Dawson,et al. Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein , 2003, Cancer Gene Therapy.
[37] J. Bell,et al. Oncolytic viruses: programmable tumour hunters. , 2002, Current gene therapy.
[38] T. DeWeese,et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. , 2001, Cancer research.
[39] J. Roth,et al. Adenovirus-mediated wild-type p53 gene expression radiosensitizes non-small cell lung cancer cells but not normal lung fibroblasts , 2001, International journal of radiation biology.
[40] Y K Cheung,et al. Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities , 2000, Biometrics.
[41] M. Teo,et al. Phase 2 Neoadjuvant Treatment Intensification Trials in Rectal Cancer: A Systematic Review. , 2018, International journal of radiation oncology, biology, physics.
[42] D. Buchsbaum,et al. Cancer Treatment with Gene Therapy and Radiation Therapy , 2013 .
[43] D. Buchsbaum,et al. Chapter seven--Cancer treatment with gene therapy and radiation therapy. , 2012, Advances in cancer research.
[44] J. Gu,et al. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.